Specifically, our results indicate that Ffar2-mediated modulation of the immune properties of intestinal ILC3 during the induction of EAE effectively ameliorates CNS autoimmunity with clinical benefit on disease progression. The gene discussed is FFAR2; the disease is Autoimmunity.